Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jun;23(6):709-14.
doi: 10.1007/s11606-008-0568-2. Epub 2008 Mar 7.

Medicare beneficiaries and free prescription drug samples: a national survey

Jennifer Tjia  1 , Becky A Briesacher, Stephen B Soumerai, Marsha Pierre-Jacques, Fang Zhang, Dennis Ross-Degnan, Jerry H Gurwitz
Affiliations

Medicare beneficiaries and free prescription drug samples: a national survey

Jennifer Tjia et al. J Gen Intern Med. 2008 Jun.

Abstract

Background: New policies regulating physician/pharmaceutical company relationships propose to eliminate access to free prescription drug samples. Little is known about the prevalence of patient activity in requesting or receiving free prescription drug samples, or the characteristics of patients who access drug samples.

Objective: To determine the prevalence of free sample access and to examine demographic, clinical, and insurance characteristics of Medicare beneficiaries who access free samples.

Design: Cross-sectional study.

Participants: A national sample of 13,847 Medicare beneficiaries participating in the fall 2004 Medicare Current Beneficiary Survey.

Measurements and main results: Prevalence of free prescription drug sample access (self-reported request for or receipt of free drug samples) and the demographic, clinical, and insurance characteristics of Medicare beneficiaries who accessed drug samples. Overall, 48.3% (95% confidence of interval [CI]: 46.6%, 49.9%) of Medicare beneficiaries reported accessing free drug samples. Access was higher among beneficiaries reporting cost-related medication nonadherence compared to those without (77.7% (95% CI: 74.5%, 80.6%) vs 43.0% (95% CI: 41.4%, 44.7%)). Multivariable analysis revealed cost-related medication nonadherence (CRN) to have the strongest relationship with accessing drug samples (adjusted odds ratio [AOR] 4.43 [95% CI: 3.64, 5.39]). Compared to beneficiaries with generous drug benefits from Medicaid, beneficiaries who lacked prescription drug benefits were more likely to access drug samples (AOR 2.42 [95% CI: 2.06, 2.85]). Beneficiaries with drug coverage from employer-sponsored plans or partial coverage (Medicare HMO, self-purchased Medicare supplement, or state-sponsored low-income plans) were also more likely to access drug samples (AOR 2.02, 1.74, respectively). Having 2-3 or > or = 4 comorbidities (vs 0-1 comorbidities) also increased the likelihood of accessing drug samples (AOR 1.60 (95% CI: 1.44, 1.79) and 2.00 (95% CI: 1.74, 2.29).

Conclusions: Accessing free prescription drug samples is prevalent among many categories of beneficiaries, especially among individuals with cost-related medication nonadherence and poor health status. Policies restricting or prohibiting drug sample distribution may adversely impact access to medications among patients in high-risk groups.

PubMed Disclaimer

Comment in

References

    1. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004;351:1885–90. doi: 10.1056/NEJMhpr042734. - DOI - PubMed
    1. Coleman DL, Kazdin AE, Miller LA, Morrow JS, Udelsman R. Guidelines for interactions between clinical faculty and the pharmaceutical industry: one medical school’s approach. Acad Med. 2006;81:154–60. doi: 10.1097/00001888-200602000-00011. - DOI - PubMed
    1. HUP/CPUP policy #1-07-10 “Guidelines for Interactions between Healthcare Professionals and Industry": Hospital of the University of Pennsylvania Clinical Practices of the University of Pennsylvania; 2006. http://www.uphs.upenn.edu/cep/resources/PhARMA%202-202006%20prof-industr.... Accessed on February 20, 2008.
    1. HUP/CPUP policy #1-12-41 “Pharmaceutical Company Representative Activity": Hospital of the University of Pennsylvania Clinical Practices of the University of Pennsylvania; 2007. http://www.uphs.upenn.edu/cep/resources/1_12_41%20pharma%20policy.pdf. Accessed on February 20, 2008.
    1. Policy and Guidelines for Interactions between the Stanford University School of Medicine, the Stanford Hospital and Clinics, and Lucile Packard Children’s Hospital with the Pharmaceutical, Biotech, Medial Device, and Hospital and Research Equipment and Supplies Industries (“Industry”): Stanford Hospital and Clinics; 2006. http://med.stanford.edu/coi/siip/policy.html Accessed on February 20, 2008.

Publication types